22-23-dihydrostigmasterol and Laryngitis fungal - from FDA reports
There is no Laryngitis fungal reported by people who take 22-23-dihydrostigmasterol yet. This review analyzes which people have Laryngitis fungal with 22-23-dihydrostigmasterol. It is created by eHealthMe based on reports from FDA, and is updated regularly.
What to expect?
Personalized health information
On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>
On Nov, 19, 2017
No report is found.
How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.
Subscribe to the study: get notified of updates to the study.
Do you have Laryngitis fungal when taking 22-23-dihydrostigmasterol?
- Check symptoms - is laryngitis fungal caused by a drug or a condition?
- Get alerts to symptoms - forecast your symptoms and get alerts
- Report the side effect - help people in need and in real time
- Ask a question - ask a question related to the study
- write a review - share your experience related to the study
- More tools...
Expand the study to include all drugs with the same ingredientsLaryngitis fungal and drugs with ingredients of beta - sitosterol.
Expand the study to include reports from both FDA and eHealthMeLaryngitis fungal and 22-23-dihydrostigmasterol from FDA and eHealthMe reports
22-23-dihydrostigmasterol has active ingredients of beta - sitosterol.
Laryngitis fungal (inflammation of the larynx due to fungal infection) has been reported by people with asthma, immunodeficiency common variable, gastroesophageal reflux disease, chronic obstructive pulmonary disease, hoarseness or changing voice (latest reports from 47 Laryngitis fungal patients).